Filing Flows › Integra Lifesciences Holdings (IART) › How it makes money
How Integra Lifesciences Holdings (IART) makes money
Integra Lifesciences Holdings (IART) made $411M of revenue in the third quarter 2026 (Q3 2026), +2% from a year earlier. Specialty Surgery brought in $304M (74%); Tissue Reconstruction brought in $107M (26%). Of every dollar of revenue, 5¢ was left as operating profit, 4¢ was left as net earnings.
Drawing the Sankey…
Revenue by segment, Q3 2026
| Segment | Revenue | Share | Q/Q | Y/Y |
|---|---|---|---|---|
| Specialty Surgery | $304M | 74.0% | -2% | +4% |
| Tissue Reconstruction | $107M | 26.0% | -2% | -2% |
Where each dollar of revenue goes
| Line | Q3 2026 | % of revenue |
|---|---|---|
| Revenue | $411M | 100.0% |
| Operating profit | $18.9M | 4.6% |
| Income tax | $812K | 0.2% |
| Net earnings | $14.9M | 3.6% |
| Operating cash flow | $96.0M | 23.3% |
| Free cash flow | $85.7M | 20.8% |
Revenue, quarter by quarter
| Quarter | Revenue | Y/Y |
|---|---|---|
| Q3 2026 | $411M | +2% |
| Q2 2026 | $419M | +0.8% |
| Q1 2026 | $392M | +2% |
| Q4 2025 | $435M | -2% |
| Q3 2025 | $402M | +6% |
| Q2 2025 | $416M | -0.6% |
| Q1 2025 | $383M | +4% |
From Integra Lifesciences Holdings' 10-Q filed Oct 23, 2026 (on EDGAR).
Questions
How does Integra Lifesciences Holdings make money?
Integra Lifesciences Holdings (IART) made $411M of revenue in the third quarter 2026 (Q3 2026), +2% from a year earlier. Specialty Surgery brought in $304M (74%); Tissue Reconstruction brought in $107M (26%). Of every dollar of revenue, 5¢ was left as operating profit, 4¢ was left as net earnings.
What is Integra Lifesciences Holdings' biggest business?
Specialty Surgery: $304M in the third quarter 2026, 74% of revenue, +4% from a year earlier.
What is Integra Lifesciences Holdings' profit margin?
Net earnings were $14.9M, 3.6% of revenue, in the third quarter 2026; the operating margin was 4.6%.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.